Evaluating the Immunopathogenesis of Diabetes after Acute Pancreatitis in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium

Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

ABSTRACT: The association between acute pancreatitis (AP) and diabetes mellitus (DM) has long been established, with the initial descriptions of AP patients presenting with DM after a bout of AP published in the 1940s and 50s. However, the potential mechanisms involved, particularly those components related to the immune system, have not been well defined. The Diabetes RElated to Acute pancreatitis and its Mechanisms (DREAM) study is a multicenter clinical study designed to understand the frequency and phenotype of DM developing after AP. This article describes one objective of the DREAM study: to determine the immunologic mechanisms of DM after AP, including the contribution of β-cell autoimmunity. This component of the study will assess the presence of islet autoimmunity, as well as the magnitude and kinetics of the innate and adaptive immune response at enrollment and during longitudinal follow-up after 1 or more episodes of AP. Finally, DREAM will evaluate the relationship between immune features, DM development, and pancreatitis etiology and severity.

Original languageEnglish (US)
Pages (from-to)580-585
Number of pages6
JournalPancreas
Volume51
Issue number6
DOIs
StatePublished - Jul 1 2022

Bibliographical note

Funding Information:
The T1DAP Consortium is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (grants U01DK127384, U01DK127367, U01DK127377, U01DK127392, U01DK127382, U01DK127403, U01DK127404, U01DK127388, U01DK127395, U01DK127378, and U01DK127400). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Funding Information:
J.A.H. consults for aTyr Pharma. F.G.S.T. has received consulting fees from Sanofi, Eli Lilly, and AstraZeneca and research support from Dompé. G.I.P. has <5% equity with Ariel Precision Medicine, has consulted with Nestle, and receives research funds from Abbvie. M.D.B. receives research support from Viacyte and Dexcom and has participated on an advisory board with Insulet. C.S. participates on an advisory board for Vertex Pharmaceuticals. The rest of the authors declare no conflict of interest.

Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.

Keywords

  • RNAseq
  • T1D
  • autoantibody
  • autoimmune
  • diabetes
  • immune system
  • Acute Disease
  • Humans
  • Insulin-Secreting Cells
  • Diabetes Mellitus, Type 1/complications
  • Pancreatitis/complications

PubMed: MeSH publication types

  • Multicenter Study
  • Journal Article
  • Research Support, N.I.H., Extramural

Fingerprint

Dive into the research topics of 'Evaluating the Immunopathogenesis of Diabetes after Acute Pancreatitis in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium'. Together they form a unique fingerprint.

Cite this